Indeed, various drug companies have directed many resources to exploit the potential of lncRNAs as drug targets.170, 171 The expression of lncRNAs can be manipulated by specific siRNAs or antisense oligonucleotides or exogenous overexpression.172, 173 Previously, a study demonstrated that introduction of tumor suppressor MEG3 into HCC tumor via a novel delivery system promoted apoptosis,163 an effect that confirms the pharmacological value of lncRNA‐based therapy as an option with few adverse effects. The gene discussed is MEG3; the disease is neoplasm.